Moseby-Knappe, Marion http://orcid.org/0000-0001-8160-5957
Mattsson-Carlgren, Niklas
Stammet, Pascal
Backman, Sofia
Blennow, Kaj
Dankiewicz, Josef
Friberg, Hans
Hassager, Christian
Horn, Janneke
Kjaergaard, Jesper
Lilja, Gisela
Rylander, Christian
Ullén, Susann
Undén, Johan
Westhall, Erik
Wise, Matt P.
Zetterberg, Henrik
Nielsen, Niklas
Cronberg, Tobias
Funding for this research was provided by:
vetenskapsrådet
Lund University
Article History
Received: 11 June 2021
Accepted: 13 July 2021
First Online: 21 August 2021
Declarations
:
: MMK, NMC, PS, SB, JD, HF, CH, JH, GL, CR, SU, JH, EW, MW, NN and TC report no conflicts of interest. HZ has served at scientific advisory boards for Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies and CogRx, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. JK reports funding from NovoNordisk foundation NNF17OC0028706, for work outside the present manuscript.
: The TTM-trial was approved by the Regional Ethical Review Board at Lund University, Sweden and by the appropriate research ethics committees in each participating country. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.